← Back to dossier
Patient handout

Severe pre-eclampsia / eclampsia (peripartum hypertensive crisis)

PRODUCTION

1. Your condition

This handout is for severe pre-eclampsia / eclampsia (peripartum hypertensive crisis). Your care team identified this based on: bp ≥160/110 in pregnancy or postpartum (acog 2020).

Other reasons your team may use this plan: severe features: severe ha, vision changes, ruq/epigastric pain, ams, low platelets, aki, transaminitis, pulmonary edema (acog 2020); seizure on background of pre-eclampsia → eclampsia (acog 2020); currently pregnant or within 6 weeks postpartum (acog 2020).

2. Your medications

Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.

MedicationStarting doseHowWhenWhat it does
labetalol20 mg IV → 40 mg → 80 mg q10 min (max 300 mg cumulative)IVbolusACOG 2020 first-line; safe in pregnancy; mortality benefit data from CHIPS (PMID 25629739)
hydralazine5-10 mg IV q15-20 min (max 30 mg cumulative)IVq15-20 minACOG 2020 alternative; less predictable BP drop than labetalol but acceptable; safe in pregnancy
nifedipine10-20 mg PO (immediate-release), repeat in 30 min if no response (max 50 mg/h cumulative)POq30 min × 2 then q4-6hACOG 2020 first-line oral option; useful when IV access pending; monitor for hypotension with concurrent MgSO4
magnesium sulfate4-6 g IV load over 20 min then 1-2 g/h infusionIVcontinuousMAGPIE (PMID 12053139) + Lucas (PMID 7494569) — primary anti-seizure prophylaxis + treatment per ACOG 2020; goal Mg 4.8-8.4 mg/dL; check reflexes + RR + UOP q1h
lorazepam2-4 mg IVIVPRN for seizure breakthrough on MgSO4Adjunct AED for refractory seizures; consider levetiracetam if recurrent
metoprolol25 mg PO BID titrate (postpartum only — not first-line antepartum)POBIDPostpartum oral BB; AVOID atenolol antepartum (FGR association); metoprolol acceptable postpartum + during lactation
AVOID ACE inhibitors / ARBs in pregnancyAVOIDN/AN/AFetotoxic — oligohydramnios, renal dysgenesis, lung hypoplasia, IUGR; FDA Pregnancy Category D; ACOG Class III in pregnancy
AVOID nitroprusside in pregnancyAVOIDN/AN/ACyanide → fetal toxicity (cyanide crosses placenta); ACOG 2020 AVOID in pregnancy
AVOID atenolol in pregnancyAVOIDN/AN/AFGR association in 1st-trimester exposure; ACOG suggests labetalol or metoprolol if BB needed
Delivery (definitive treatment)Per OB judgment — induction vs C-section based on severity + cervical readinessOR_or_LDas neededACOG 2020 — delivery is curative; ≥34 wk severe → deliver; <34 wk severe → individualized with steroids + MgSO4 + tertiary center transfer

Plan: Severe pre-eclampsia / eclampsia — pregnancy-safe BP control + MgSO4 seizure prophylaxis + delivery as definitive Tx

3. When to call your provider

Contact your care team if any of the following happen:

  • BP rebound → escalate per HTN ladder
  • Subsequent pregnancy → preconception counseling + early aspirin

4. When to seek emergency care

Call 911 or go to the nearest emergency room right away if you have:

  • Recurrent seizure during MgSO4 infusion — requires reload + benzodiazepine + emergent delivery(life-threatening)
  • HELLP syndrome with platelets <50k OR LDH >600 OR worsening transaminitis — high risk for hepatic hemorrhage + DIC(life-threatening)
  • Loss of patellar reflexes OR RR <12 OR UOP <20 mL/h on MgSO4 — signs of magnesium toxicity (Mg >9 mg/dL)(life-threatening)
  • Vaginal bleeding + uterine tenderness + non-reassuring fetal HR + severe pre-eclampsia — placental abruption(life-threatening)
  • Eclampsia seizure occurring postpartum (up to 6 weeks after delivery) — late postpartum eclampsia(life-threatening)

5. Follow-up

Postpartum: continue MgSO4 24 h post-delivery; transition to oral labetalol or nifedipine for postpartum HTN; 1-2 wk postpartum BP check; 3-mo cardiology + nephrology assessment; lifetime CV risk elevation discussion (pre-eclampsia is independent CV risk factor)

6. Sources

Guideline: ACOG Practice Bulletin 222 (2020/2022) Severe Pre-eclampsia + 2025 ACC/AHA HTN (Whelton) + ESC/ESH 2024 HTN (Mancia PMID 38613493)

  1. pubmed.ncbi.nlm.nih.gov/38316810
  2. pubmed.ncbi.nlm.nih.gov/38613493
  3. pubmed.ncbi.nlm.nih.gov/12053139